Skip to main content
Sign In

University of Colorado Denver Hematology, Blood Cancer, Bone Marrow Transplant Program

 Blood Cancer, Bone Marrow Transplant Program Logo
 

Clinical Trials

​See what human subject trials are accepting applicants


For more information click the study identifier or search the identifier number at clinicaltrials.gov.

 Acute Lymphoblastic Leukemia (non transplant)

ClinicalTrials.gov
Identifier
Study Title ​Study Coordinator
NCT02535364​ ​A Phase 2, Single-arm, Multicenter Trial to Determine the Efficacy and Safety of JCAR015 in Adult Subjects With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia ​Kayla Fischer, 720-848-2409​​
​​1

 Acute Myeloid Leukemia (non-transplant)

 
ClinicalTrials.gov
Identifier
Study Title Study Coordinator​
NCT02492737​ ​A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Stud​​y of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation. Natalie Monson, 720-848-2199

NCT02335814​​

​Phase 1/1b, First-in-Human, Dose-Escalation and Expansion Study of FLX925 Administered Orally to Subjects With Relapsed or Refractory Acute Myeloid Leukemia. Natalie Monson, 720-848-2199
​NCT02203773 ​A Phase​ 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment Naive Subjects With Acute Myelogenous Leukemia Who Are Greater Than or Equal to 65 Years of Age and Who Are Not Eligible for Standard Induction Therapy. ​Therese Jones, 720-848-8029

NCT02074839​​​​

​A Phase I, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation. Rachel Freeby, 720-848-0736​
NCT00840177 ​S0919, A Phase II Study of Idarubicin and Ara-C in Combination with Pravastatin for Relapsed Acute Myelogenous Leukemia (AML) Emily Denoncourt, 720-848-0566

NCT02472145

​A Randomized Phase 2/3 Study of DACOGEN® (Decitabine) Plus JNJ-56022473 (Anti CD123) Versus DACOGEN (Decitabine) Alone in Patients With AML Who Are Not Candidates for Intensive Chemotherapy Shirstine Rahkola, 720-848-1776​
NCT02670044 ​A Phase IB/II Multi-Arm Study With Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy ​Shirstine Rahkola, 720-848-1776​​
​NCT02632708​ ​A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination With Induction Therapy and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation ​Tricia Feddick, 720-848-8034​

​​​​​​​​​​​​​​​​​​10

 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (non transplant)

ClinicalTrials.gov
Identifier
Study Title Study Coordinator​
NCT01886859 A Dose Escalation Study of Ibrutinib with Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma ​Nicole Adler, 720-848-0678

NCT02475681

A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination With Chlorambucil, ACP-196 in Combination With Obinutuzumab, and ACP-196 Monotherapy in Subjects With Previously Untreated CLL

Natalie Monson, 720-848-2199

​​​2

 Hodgkin Lymphoma (non transplant)

No current trials recruiting3

 Myelodysplastic Syndrome (non transplant)

ClinicalTrials.gov
Identifier
Study Title Study Coordinator​
​NCT02492737​ ​A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation. Natalie Monson, 720-848-2199​
NCT02074839 ​A Phase I, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation.

Rachel Freeby, 720-848-0736​

NCT02706899​ ​​​A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) in Combination With Azacitidine in Patients With Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High Risk Myelodysplastic Syndrome (MDS) Megan McClain, 720-848-3773​​​​

4

 Myeloma (non transplant)

ClinicalTrials.gov Identifier Study Title Study Coordinator
NCT02492737​ ​A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation. ​Natalie Monson, 720-848-2199​
NCT02576977 ​ ​A Phase III Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (KEYNOTE 183) ​Therese Jones, 720-848-8029​​
​​​5

 Non Hodgkin Lymphoma: Follicular & other indolent (non transplant)

ClinicalTrials.Gov
Identifier
Study Title Study Coordinator
NCT02257567​ ​A phase IB/II study evaluating the safety, tolerability and anti-tumor activity of polatuzumab vedotin (dcds4501a) in combination with rituximab (r) or obinutuzumab (g) and bendamustine (b) in relapsed or refractory follicular or diffuse large b-cell lymphoma. ​Emily Denoncourt, 720-848-0566
​​6

 Non Hodgkin Lymphoma: Mantle Cell (non transplant)

​No current trials recruiting7

 Non Hodgkin Lymphoma: DLBCL and other aggressive (non transplant)

ClinicalTrials.Gov
Identifier
Study Title Study Coordinator
​NCT02492737​ ​A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation. ​Natalie Monson, 720-848-2199​
NCT02257567​ ​A phase IB/II study evaluating the safety, tolerability and anti-tumor activity of polatuzumab vedotin (dcds4501a) in combination with rituximab (r) or obinutuzumab (g) and bendamustine (b) in relapsed or refractory follicular or diffuse large b-cell lymphoma. ​Emily Denoncourt, 720-848-0566
NCT02567656​  ​A Phase I/Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed or Refractory T-cell Lymphoma ​Kelsey Moore, 720-848-8089​​
​​​​​8

 Transplant

ClinicalTrials.Gov
Identifier
Study Title Study Coordinator​
​NCT01841333 ​A Phase 2 Study of PF-04449913 for the Treatment of Acute Leukemia Patients with High Risk of Post-Allogeneic Stem Cell Transplantation Relapse ​​Emily Denoncourt,
720-848-0566
​​9